Compugen Ltd (CGEN) 8.38 $CGEN
Compugen Has Returned 13.5% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu May 08, 9:59AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 1 month, Compugen has returned 13.46% as of today's recent price of $8.97.
Research and Markets: Compugen Ltd. - Product Pipeline Review 2014
Business Wire - Wed May 07, 8:58PM CDT
Research and Markets (http://www.researchandmarkets.com/research/765jtc/compugen_ltd) has announced the addition of the "Compugen Ltd. - Product Pipeline Review - 2014" company profile to their offering.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Compugen Ltd. - Product Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwxqkw/compugen_ltd) has announced the addition of the "Compugen Ltd. - Product Pipeline Review - 2014" company profile to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of Compugen Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides brief overview of Compugen Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Compugen Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Compugen Ltd.'s pipeline products Reasons to buy - Evaluate Compugen Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Compugen Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Compugen Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Compugen Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Compugen Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Compugen Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues For more information visit http://www.researchandmarkets.com/research/mw...mpugen_ltd
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Compugen First Quarter 2014 Conference Call Scheduled for Monday, May 19, 2014 at 10:00 AM EST
Business Wire - Mon May 05, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EST on Monday, May 19, 2014 to review the first quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.
Compugen to Present at Immunology 2014 Conference
Business Wire - Tue Apr 29, 6:31AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that it will present at the Immunology 2014 Conference to be held May 2-6 in Pittsburgh. Immunology 2014, the annual meeting of the American Association of Immunologists, is a premier international scientific meeting at which world leaders in immunology present their research. Compugen's presentation will take place in a session entitled "Harnessing Cellular and Molecular Interactions in Autoimmunity" on Tuesday, May 6, 2014.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Downtrend Call Working As Compugen Stock Falls 9.6% (CGEN)
Comtex SmarTrend(R) - Tue Apr 15, 10:07AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 3 weeks, Compugen has returned 9.60% as of today's recent price of $9.37.
Compugen Statement Regarding Insider Trading Allegations
Business Wire - Mon Apr 07, 8:03AM CDT
Compugen Ltd. (NASDAQ: CGEN) issued the following statement today.
Biosimulation Trends - Global Market Overview 2014-2017
M2 - Thu Apr 03, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bclc3f/biosimulation) has announced the addition of the "Biosimulation Trends" report to their offering. Biosimulation is the mathematical simulation of complex, large biological processes on a computer. Biosimulation is being adopted at a faster pace, to extract and interpret vital data from experiments during drug discovery and development. The report analyzes and presents an overview of Biosimulation market worldwide. The report provides global market estimates and projections for Biosimulation in US dollars for the years 2012 through 2017. Supported with 1 market data table, the report highlights the ever increasing permanence of Biosimulation. The report also provides a review of Biosimulation Models, and Biosimulation software. Key Topics Covered: 1. BIOSIMULATION - A MARKET OVERVIEW - A Prelude - Biosimulation - Revolutionizing Drug Discovery - Biosimulation - Models - Biosimulation Software 2. RECENT INDUSTRY ACTIVITY - Accelrys Introduces Discovery Studio 3.5 - Rhenovia Pharma Introduces Drug Development Programs for Orphan, Neglected and Rare Neurodegenerative Diseases - Rhenovia Pharma Sets Up International Subsidiary in the US - Rhenovia Pharma Inks an Agreement with Portmann - Entelos and RegeneMed Introduce iToxFX Service 3. MARKET PARTICIPANTS - Accelrys, Inc. - Advanced Chemistry Development, Inc. - Anoixis Corporation - Aptiv Solutions - Chemical Computing Group, Inc. - Cognigen Corporation - Compugen Ltd. - Entelos, Inc. - Genedata AG - GNS Healthcare - Immunetrics, Inc. - INOSIM Software GmbH - Insilico Biotechnology AG - Kinetigen, Inc. - LeadInvent - Leadscope, Inc. - Molecular Knowledge Systems, Inc. - Nimbus Discovery LLC - Novo Nordisk A/S - Open Eye Scientific Software, Inc. - Optimata Ltd. - PhinC Development - Physiomics PLC - Rhenovia Pharma SAS - Rosa & Company LLC - Schrodinger LLC - Simcyp Ltd. - Tessella Ltd. - TheraSim - VirtuCel, Inc. 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/bc...simulation
18.3% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 20, 11:13AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 18.31% as of today's recent price of $11.76.
Will 'Buy' Rating Help Compugen (CGEN) Today?
at The Street - Wed Mar 19, 8:55AM CDT
Compugen CGEN was given a "buy" rating with a price target of $17 by analysts at Jefferies Group.
Compugen Up 14.4% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 13, 10:11AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 14.39% as of today's recent price of $11.37.
Compugen's Microsoft Licensing Solutions Expertise Reaffirmed
Marketwire - Tue Mar 11, 10:01AM CDT
Compugen Inc. is pleased to announce that as part of Microsoft Canada's comprehensive assessment of its partners' capabilities, Compugen will continue to retain the Licensing Solutions Partner (LSP) Authorization for Canada.
Uptrend Call Working As Compugen Stock Rises 19.7% (CGEN)
Comtex SmarTrend(R) - Thu Mar 06, 9:24AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 19.72% as of today's recent price of $11.90.
Compugen concludes public offering of 6.9m ordinary shares
M2 - Thu Mar 06, 5:21AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA), based in Israel, revealed on Wednesday the completion of its public offering of 6.9m ordinary shares at a price of USD10.50 per share.
Compugen Has Returned 13.5% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu May 08, 9:59AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 1 month, Compugen has returned 13.46% as of today's recent price of $8.97.
Research and Markets: Compugen Ltd. - Product Pipeline Review 2014
Business Wire - Wed May 07, 8:58PM CDT
Research and Markets (http://www.researchandmarkets.com/research/765jtc/compugen_ltd) has announced the addition of the "Compugen Ltd. - Product Pipeline Review - 2014" company profile to their offering.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Compugen Ltd. - Product Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwxqkw/compugen_ltd) has announced the addition of the "Compugen Ltd. - Product Pipeline Review - 2014" company profile to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of Compugen Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides brief overview of Compugen Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Compugen Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Compugen Ltd.'s pipeline products Reasons to buy - Evaluate Compugen Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Compugen Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Compugen Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Compugen Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Compugen Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Compugen Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues For more information visit http://www.researchandmarkets.com/research/mw...mpugen_ltd
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Compugen First Quarter 2014 Conference Call Scheduled for Monday, May 19, 2014 at 10:00 AM EST
Business Wire - Mon May 05, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EST on Monday, May 19, 2014 to review the first quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.
Compugen to Present at Immunology 2014 Conference
Business Wire - Tue Apr 29, 6:31AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that it will present at the Immunology 2014 Conference to be held May 2-6 in Pittsburgh. Immunology 2014, the annual meeting of the American Association of Immunologists, is a premier international scientific meeting at which world leaders in immunology present their research. Compugen's presentation will take place in a session entitled "Harnessing Cellular and Molecular Interactions in Autoimmunity" on Tuesday, May 6, 2014.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Downtrend Call Working As Compugen Stock Falls 9.6% (CGEN)
Comtex SmarTrend(R) - Tue Apr 15, 10:07AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 3 weeks, Compugen has returned 9.60% as of today's recent price of $9.37.
Compugen Statement Regarding Insider Trading Allegations
Business Wire - Mon Apr 07, 8:03AM CDT
Compugen Ltd. (NASDAQ: CGEN) issued the following statement today.
Biosimulation Trends - Global Market Overview 2014-2017
M2 - Thu Apr 03, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bclc3f/biosimulation) has announced the addition of the "Biosimulation Trends" report to their offering. Biosimulation is the mathematical simulation of complex, large biological processes on a computer. Biosimulation is being adopted at a faster pace, to extract and interpret vital data from experiments during drug discovery and development. The report analyzes and presents an overview of Biosimulation market worldwide. The report provides global market estimates and projections for Biosimulation in US dollars for the years 2012 through 2017. Supported with 1 market data table, the report highlights the ever increasing permanence of Biosimulation. The report also provides a review of Biosimulation Models, and Biosimulation software. Key Topics Covered: 1. BIOSIMULATION - A MARKET OVERVIEW - A Prelude - Biosimulation - Revolutionizing Drug Discovery - Biosimulation - Models - Biosimulation Software 2. RECENT INDUSTRY ACTIVITY - Accelrys Introduces Discovery Studio 3.5 - Rhenovia Pharma Introduces Drug Development Programs for Orphan, Neglected and Rare Neurodegenerative Diseases - Rhenovia Pharma Sets Up International Subsidiary in the US - Rhenovia Pharma Inks an Agreement with Portmann - Entelos and RegeneMed Introduce iToxFX Service 3. MARKET PARTICIPANTS - Accelrys, Inc. - Advanced Chemistry Development, Inc. - Anoixis Corporation - Aptiv Solutions - Chemical Computing Group, Inc. - Cognigen Corporation - Compugen Ltd. - Entelos, Inc. - Genedata AG - GNS Healthcare - Immunetrics, Inc. - INOSIM Software GmbH - Insilico Biotechnology AG - Kinetigen, Inc. - LeadInvent - Leadscope, Inc. - Molecular Knowledge Systems, Inc. - Nimbus Discovery LLC - Novo Nordisk A/S - Open Eye Scientific Software, Inc. - Optimata Ltd. - PhinC Development - Physiomics PLC - Rhenovia Pharma SAS - Rosa & Company LLC - Schrodinger LLC - Simcyp Ltd. - Tessella Ltd. - TheraSim - VirtuCel, Inc. 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/bc...simulation
18.3% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 20, 11:13AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 18.31% as of today's recent price of $11.76.
Will 'Buy' Rating Help Compugen (CGEN) Today?
at The Street - Wed Mar 19, 8:55AM CDT
Compugen CGEN was given a "buy" rating with a price target of $17 by analysts at Jefferies Group.
Compugen Up 14.4% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 13, 10:11AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 14.39% as of today's recent price of $11.37.
Compugen's Microsoft Licensing Solutions Expertise Reaffirmed
Marketwire - Tue Mar 11, 10:01AM CDT
Compugen Inc. is pleased to announce that as part of Microsoft Canada's comprehensive assessment of its partners' capabilities, Compugen will continue to retain the Licensing Solutions Partner (LSP) Authorization for Canada.
Uptrend Call Working As Compugen Stock Rises 19.7% (CGEN)
Comtex SmarTrend(R) - Thu Mar 06, 9:24AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 19.72% as of today's recent price of $11.90.
Compugen concludes public offering of 6.9m ordinary shares
M2 - Thu Mar 06, 5:21AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA), based in Israel, revealed on Wednesday the completion of its public offering of 6.9m ordinary shares at a price of USD10.50 per share.
